Member Info for jackdaw99

If they did, do you think they would tell you?

Considering what might soon happen to MTFB that might have been very bad timing!

Good job we are all blind Hottie, else all of your posts would be utterly redundant!

lively today,

Sounds like the only person with any news is yourself Trev!

If there was any it would likely be in an RNS Trev - clinical trial is not usually the sort of thing that leaks.

It is not actually the "technical" definition, which is "..funds owed to other businesses or creditors that must be paid within a year of the balance sheet date. The most common entries under accounts payable are ordinary expenses such as utility bills and other recurring operating costs." I'm assuming that, with offices in the US, they do have operating costs. You can find that definition anywhere you care to look. Anyway, I'm not arguing that they don't have a lot of debt but I do think, like many other businesses (Amazon etc for years) that they have taken a calculated risk on things coming good. Kromek did pretty well, MTFB may still do very well, perhaps even Datatern, so you can't really write a business off for taking risks, else there would be little industry of any kind.

Liabilities are debt are not the same thing, although liabilities can (but not necessarily) include short-term debt. So, to calculate the true level of debt you would need to know how the $10 million or so in "accounts payable" breakdown into short-term debt and other items such as operating costs. I don't know that, so best say borrowing is somewhere between $20-30 million. Agreed it's not $3 million.

Details as at 2016 year-end are here: https://www.investing.com/equities/amphion-innovations-plc-balance-sheet Debt proper seems to be $20 million.

Looks like MTFB just might be back on the rise, in which case AMP's debt problems may disappear (see surfi post below) and may be very good time to buy into AMP? Let's see if MTFB holds this week.

Thanks Surfi, for the first sensible comment in ages. And, on the even more positive side, there is still possible good news in the Datatern case and in their other investments. Still a lot to play for here.

In that case Trev, be careful what you say in public!

Agree. Summary IMO: short term = not much, medium term = possibility of at least one blindness/stroke treatment causing excitement, long term = exosomes targeting difficult problem of solid tumours. One for the pension rather than the traders?

Buying a new car?

.....strong day today. Consolidation looks sound.

Was he an accountant by any chance?

Interesting, perhaps, that she has recent NASDAQ listing experience?

... for likely numbers of patients: "Kymriah is approved for patients 25 years old and younger who have B-cell acute lymphoblastic leukemia, and whose disease has relapsed at least twice or is still detectable after other treatment. In a clinical trial, the therapy left 83 percent of such patients cancer-free after three months. STAT notes that only a few hundred patients per year may be eligible for the cell therapy. Priced at $475,000, it will be offered at just 32 sites around the country." From todays "The Scientist"

Yes. The truth unfortunately is that we know nothing about the future.

IMO. After the 10-0 recommendation, some already priced in. Institutions may well initiate purchase although, through worked buys over time, you may not see it until the % RNS. I'm not sure that's happening yet and they may need a bit more surety about actual income, or other streams from related illnesses, before they commit. It will still be seen as relatively risky by some fund managers remember! However, I do expect a steady rise from these levels, but at a slower rate and perhaps to a lower peak, than some optimists might expect. On the bear side we have the massive dilution that has occurred since the early days, while on the bull side we have the massive valuations of some similar (not identical) outfits Stateside.